Investigating Generic And Brand Name Pharmaceutical’S Market Shares And Prices In Tunisia
The purpose of this paper is to investigate how the brand name’s market shares in Tunisia are affected by generic competition during the pre-reform period of the Tunisian health insurance system following the methodological approach developed by Aronsson et al. (2001). In this study we use data for three molecules Captopril (antihypertensive) Glibenclamide (antidiabetic) and Carbamazepine (antiepileptic) from IMS Health database. The data span from the third quarter 2002 to second quarter 2007. Statistical results indicate that the impact of generic competition seems to be not different across markets (Captopril, Glibenclamide and Carbamazepine) in Tunisia. In addition, the relative price has a positive and significant effect on the change of market share of the brand name drug in Tunisia for the three active molecules. The higher the price of the brand name product relative to the average price of the generic substitutes, the smaller the decrease of market share of the brand name product. In Tunisian pharmaceutical market, brand- names charge a higher price than their generic versions and still obtain positive market shares. Thus, from a policy perspective, the large market share of higher priced brand-names relative to their generic versions is an unsatisfactory outcome taking into account that brand name drug and generics are identical products and provide similar health gains to patients.
|Date of creation:||Jul 2009|
|Date of revision:||Jul 2009|
|Publication status:||Published by The Economic Research Forum (ERF)|
|Contact details of provider:|| Postal: |
Web page: http://www.erf.org.eg
More information through EDIRC
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Nina Pavcnik, 2002. "Do Pharmaceutical Prices Respond to Potential Patient Out-of-Pocket Expenses?," RAND Journal of Economics, The RAND Corporation, vol. 33(3), pages 469-487, Autumn.
- Danzon, Patricia M & Chao, Li-Wei, 2000. "Does Regulation Drive out Competition in Pharmaceutical Markets?," Journal of Law and Economics, University of Chicago Press, vol. 43(2), pages 311-57, October.
- Richard G. Frank & David S. Salkever, 1995.
"Generic Entry and the Pricing of Pharmaceuticals,"
NBER Working Papers
5306, National Bureau of Economic Research, Inc.
- Dranove, David, 1989. "Medicaid Drug Formulary Restrictions," Journal of Law and Economics, University of Chicago Press, vol. 32(1), pages 143-62, April.
- Judith K. Hellerstein, 1998. "The Importance of the Physician in the Generic Versus Trade-Name Prescription Decision," RAND Journal of Economics, The RAND Corporation, vol. 29(1), pages 108-136, Spring.
- Joan Costa-Font & Panos Kanavos & Joan Rovira, 2007. "Determinants of out-of-pocket pharmaceutical expenditure and access to drugs in Catalonia," Applied Economics, Taylor & Francis Journals, vol. 39(5), pages 541-551.
When requesting a correction, please mention this item's handle: RePEc:erg:wpaper:497. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Namees Nabeel)
If references are entirely missing, you can add them using this form.